Page 27 - பல்கலைக்கழகம் மருத்துவமனை சவுத்தாம்ப்டன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Telix Pharmaceuticals Limited: TLX66 Meets Study Objectives in Patients with AL Amyloidosis 9 Y-besilesomab) has met study objectives, demonstrating the initial safety profile in patients with Systemic Amyloid Light Chain Amyloidosis (AL amyloidosis). The TRALA trial ( AL Amyloidosis) is a Phase I/IIa trial to evaluate the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem cell transplantation (HSCT) in patients with AL amyloidosis. 1 The TRALA trial was sponsored by University Hospital Southampton in Southampton U.K. and run across four centres: Southampton, University College Hospital London, Royal Free Hospital London, and Queen Elizabeth Hospital Birmingham. All study data were reviewed by the trial s Independent Data Monitoring Committee (IDMC).

United kingdomUnited statesUniversity collegeNew south walesCity ofStewart holmstromColin haywardChristian behrenbruchTelix pharmaceuticalsUniversity college hospital londonData monitoring committeeConsultant hematologist at university hospital southamptonUniversity hospital southampton inEuropean unionCorporate communicationsTelix pharmaceuticals limited